Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 10,608 |
|
|||||
| News | - | ||||||
| Day High | 16.78 | Low High |
|||||
| Day Low | 16.05 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Curis Inc | CRIS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.15 | -0.91% | 16.36 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.78 | 16.05 | 16.78 | 16.36 | 16.51 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 318 | 10,608 | $ 16.39 | $ 173,903 | - | 3.80 - 19.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:47:45 | 2 | $ 15.85 | USD |
Curis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 97.25M | 5.89M | - | 10.02M | -47.41M | -8.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Curis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRIS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.44 | 16.99 | 14.24 | 15.54 | 10,358 | 1.92 | 13.30% |
| 1 Month | 15.84 | 17.49 | 13.9914 | 15.64 | 18,628 | 0.52 | 3.28% |
| 3 Months | 10.33 | 17.49 | 9.04 | 12.90 | 26,538 | 6.03 | 58.37% |
| 6 Months | 4.56 | 17.49 | 4.53 | 10.47 | 63,273 | 11.80 | 258.77% |
| 1 Year | 16.976 | 19.60 | 3.80 | 13.30 | 159,509 | -0.616 | -3.63% |
| 3 Years | 214.64 | 348.00 | 3.80 | 87.16 | 1,388,865 | -198.28 | -92.38% |
| 5 Years | 36.00 | 348.00 | 3.80 | 96.84 | 1,571,351 | -19.64 | -54.56% |
Curis Description
| Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
